Immunogenic Cell Death

Immunogenic Cell Death (ICD) and Cancer Immunotherapy

Immunogenic cell death (ICD) represents a distinct form of strategy in oncology, where dying cancer cells are converted into stimuli that drive long-lasting antitumor immunity (i.

Immunogenic Cell Death (ICD)

Immunogenic cell death (ICD) represents a distinct form of strategy in oncology, where dying cancer cells are converted into stimuli that drive long-lasting antitumor immunity (i.

Nanomaterial-Based Tumor Therapy Targeting Mitochondrial Metabolism

Nanomaterial-based therapy targeting mitochondrial metabolism uses engineered carriers or reactive platforms to concentrate drugs, metals, photosensitizers, or metabolic inhibitors in tumors and then direct their action toward mitochondrial functions.

Complexity of Cell Death-Induced Inflammation

Cell death-induced inflammation is not a fixed property of one death morphology.

Epigenetics and Cell Death in Cancer Therapy

Epigenetics regulates gene activity without changing DNA sequence through DNA methylation, histone modification, chromatin remodeling, non-coding RNAs, and RNA modifications.

RCDs in Tumor Metabolism and Tumor Immunity

Metabolic context determines death susceptibility.

Immunological advantages of in situ vaccines

An in situ cancer vaccine turns a patient’s tumor into the source of antigen and immune priming.

Immune-activating effects of oncolytic virus therapy

Oncolytic viruses are designed or selected to infect and replicate preferentially in malignant tissue, causing tumor lysis while stimulating immunity.

Tumor-Busting: Cancer-Mimicking Peptide Immunotherapy

Cancer-mimicking peptide immunotherapy uses altered peptides, mimotopes, or selected peptide ligands to provoke immunity that cross-recognizes a tumor antigen.

Cancer vaccines and immunotherapy

Therapeutic cancer vaccines aim to generate or amplify immune responses against antigens expressed by an established tumor.

Neoadjuvant immunotherapy and cancer treatment

Neoadjuvant immunotherapy treats a resectable cancer before surgery, when the primary tumor and its draining lymphatic network remain available as sources of antigen and immune priming.

Advances in Breast Cancer Immunotherapy

Breast cancer was historically considered less immunogenic than melanoma or lung cancer, but that view changed as molecular subtypes, tumor-infiltrating lymphocytes, and checkpoint responses were studied separately.

Radiation and Tumor Immune Microenvironment

Radiotherapy is no longer viewed only as a local method for damaging tumor DNA.

Cancer Phototherapy: Mechanisms, Challenges, And Innovations

Cancer phototherapy uses light-activated agents or optical energy to destroy malignant tissue through localized chemical, thermal, or immune-mediated damage.

Cancer Immune Evasion: The "Three Cs" Model

Cancer immune evasion describes the capacity of malignant cells to avoid immune recognition, resist immune elimination, and establish progressive disease despite antitumor immunity.

Therapeutic Antibodies For Targeted Cancer Therapy

Therapeutic antibodies for targeted cancer therapy are engineered proteins that bind tumor antigens, immune checkpoints, or stromal regulators to block oncogenic signaling, recruit immune effector functions, or deliver cytotoxic payloads.

The Dual Role Of Viruses In Cancer: Carcinogenic And Anti-Cancer Immunity

The dual role of viruses in cancer reflects two opposing biological capacities: oncogenic viruses can initiate or promote malignant transformation, while engineered or naturally selected oncolytic viruses can destroy tumors and stimulate antitumor immunity.

Tumor Organoids Drive The Development Of Cancer Nanomedicine

Tumor organoids drive cancer nanomedicine by providing three-dimensional, patient-derived models that preserve key tumor architecture, molecular features, histopathology, genetic traits, phenotypes, and tumor microenvironment interactions.

Photosensitizers: Enabling Precise, In Situ Tumor Destruction

Photosensitizers enable precise, in situ tumor destruction through photodynamic therapy, a two-stage cancer treatment that administers a photosensitizing agent and then illuminates the target lesion with light of an appropriate wavelength in the presence of molecular oxygen.

Crosstalk Between Cuproptosis And Antitumor Immunity

Cuproptosis describes copper-dependent regulated cell death linked to mitochondrial metabolism, and its connection with antitumor immunity has become a fast-growing theme in cancer biology.

The Guiding Significance of Erythrocyte "Spectosis".

Spectosis is a lytic programmed cell death pathway in mature red blood cells triggered by complement activation and involving NLRP3 signaling.

dsRNA: A Key Mediator of Cancer & Beyond

Double-stranded RNA (dsRNA) was initially characterized as a molecular signature of viral infection, but accumulating evidence shows that endogenous dsRNA also arises from host-derived sources including endogenous retroviruses, transposable elements, mitochondrial transcripts, and sense-antisense transcription.

Vaccine Formulation: From Adjuvants to RNA Delivery Systems

Vaccine formulation integrates antigens, adjuvants, and delivery systems to enhance immunogenicity and shape the magnitude, breadth, and durability of immune responses.

Photodynamic Therapy: Past, Current, Future

Photodynamic therapy (PDT) is a light-activated therapeutic modality that combines photosensitizers, oxygen, and specific light wavelengths to generate reactive oxygen species for selective cellular destruction.